Across TCGA pan-cancer cohorts, UBA52 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated UBA52 data layer compared with 18 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher UBA52 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UBA52 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LIHC, BLCA, and CESC are the cancer types where UBA52 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.059	0.777	<.001	36	view →
BLCA	OS	Median	II,III,IV	1.000	0.408	.020	16	view →
CESC	OS	Median	All	0.087	0.585	.034	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: UBA52 tumor-vs-normal RNA expression · all UBA52 data types